Carbamazepine parenteral nanoemulsions prepared by spontaneous emulsification process

被引:149
作者
Kelmann, Regina G.
Kuminek, Gislaine
Teixeira, Helder F.
Koester, Letfcia S.
机构
[1] Univ Fed Santa Catarina, Ctr Ciencuas Saude, Dept Ciencias Farmaceut, Lab Controle Qualidade, BR-88040900 Florianopolis, SC, Brazil
[2] Univ Fed Rio Grande do Sul, Fac Farm, BR-90610000 Porto Alegre, RS, Brazil
关键词
carbamazepine; nanoemulsions; intravenous; spontaneous emulsification; factorial design;
D O I
10.1016/j.ijpharm.2007.05.004
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Carbamazepine (CBZ), a widely used anticonvulsant drug, is a poorly soluble drug with no parenteral treatment available for patients. This study was aimed at developing a nanoemulsion for CBZ intravenous delivery. The spontaneous emulsification method was used to prepare different formulations containing 2 mg/mL CBZ. Likewise, a 2(2) full factorial experimental design was applied to study the influence of two independent variables (type of oil and type of lipophilic emulsifier) on emulsion physicochemical characteristics. The nanoemulsions were evaluated concerning droplet size, zeta potential, viscosity, drug content and association to oily phase. The formulation, which presented the best characteristics required for intravenous administration was selected and refined with respect to the lipophilic emulsifier content (increase from 5% to 6% of soy lecithin). This formulation was characterized and kept its properties in a satisfactory range over the evaluated period (3 months), i.e. droplet size around 150 nm, drug content around 95% and zeta potential around -40 mV. The transmission electron microscopy revealed emulsion droplets almost spherical in shape with an amorphous core, whereas the in vitro release profile assessed by dialysis bags demonstrated a release kinetics square root time dependent, with 95% of ca. having been released within 11 h. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:231 / 239
页数:9
相关论文
共 50 条
[1]
Abrol Sonia, 2005, Current Drug Delivery, V2, P45, DOI 10.2174/1567201052772870
[2]
Formulation of intravenous Carbamazepine emulsions by SolEmuls® technology [J].
Akkar, A ;
Müller, RH .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2003, 55 (03) :305-312
[3]
Becirevic-Lacan Mira, 2002, Acta Pharmaceutica (Zagreb), V52, P149
[4]
SUBMICRON EMULSIONS AS COLLOIDAL DRUG CARRIERS FOR INTRAVENOUS ADMINISTRATION - COMPREHENSIVE PHYSICOCHEMICAL CHARACTERIZATION [J].
BENITA, S ;
LEVY, MY .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1993, 82 (11) :1069-1079
[5]
Nano-emulsion formulation using spontaneous emulsification:: solvent, oil and surfactant optimisation [J].
Bouchemal, K ;
Briançon, S ;
Perrier, E ;
Fessi, H .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 280 (1-2) :241-251
[6]
Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of carbamazepine in the dog: Comparison with commercially available tablets and suspensions [J].
Brewster, ME ;
Anderson, WR ;
Meinsma, D ;
Moreno, D ;
Webb, AI ;
Pablo, L ;
Estes, KS ;
Derendorf, H ;
Bodor, N ;
Sawchuk, R ;
Cheung, B ;
Pop, E .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (03) :335-339
[7]
CHAUBAL MV, 2006, PHARM TECHNOL 1002
[8]
Tocol emulsions for drug solubilization and parenteral delivery [J].
Constantinides, PP ;
Tustian, A ;
Kessler, DR .
ADVANCED DRUG DELIVERY REVIEWS, 2004, 56 (09) :1243-1255
[9]
Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel [J].
Constantinides, PP ;
Lambert, KJ ;
Tustian, AK ;
Schneider, B ;
Lalji, S ;
Ma, WW ;
Wentzel, B ;
Kessler, D ;
Worah, D ;
Quay, SC .
PHARMACEUTICAL RESEARCH, 2000, 17 (02) :175-182
[10]
Modeling and comparison of dissolution profiles [J].
Costa, P ;
Manuel, J ;
Lobo, S .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) :123-133